289 results on '"Chang, Chun‐Ping"'
Search Results
2. Supplementary Table S2 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
3. Supplementary Table S1 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
4. Supplementary Figure S6 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
5. Supplementary Table S2 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
6. Data from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
7. Supplementary Figure S2 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
8. Supplementary Figure S3 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
9. Supplementary Figure S7 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
10. Supplementary Table S1 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
11. Supplementary Figure S8 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
12. Supplementary Figure S1 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
13. Supplementary Figure S8 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
14. Supplementary Figure S7 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
15. Supplementary Figure S6 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
16. Supplementary Figure S2 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
17. Supplementary Figure S5 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
18. Supplementary Figure S4 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
19. Supplementary Figure S3 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
20. Supplementary Figure S1 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
21. Supplementary Materials and Methods from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
22. Supplementary Figure S4 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
23. Data from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
24. Supplementary Materials and Methods from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
25. Supplementary Figure S5 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
26. How does political instability affect renewable energy innovation?
27. The Relationship Between Money Supply and Stock Return, Before and After Quantitative Easing Policy
28. Left vs right: Who works better at achieving sustainability?
29. How firm’s perception of economic policy uncertainty influences innovation quality
30. Do renewable energy investment and financial development mitigate climate change?
31. Understanding the Key Determinants of Fiji's Renewable Energy
32. CSR from different perspectives: The global ESG indexes updated
33. Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus
34. Green innovation, industrial structure and urban eco-efficiency in Chinese cities
35. Assessing the impact of religion on environmental quality
36. The impact of economic sanctions on the COVID-19 pandemic
37. Environmental fees, local competition, and corporate green innovation activities: evidence from China
38. Carbon tax: Catalyst or hindrance for renewable energy use in climate change mitigation?
39. Going green with artificial intelligence: The path of technological change towards the renewable energy transition
40. Pulmonary delivery of remdesivir and dexamethasone encapsulated nanostructured lipid carriers for enhanced inflammatory suppression in lung
41. The Choice Between FDI and Selling Out with Externality and Exchange Rate
42. Performance of the Initial Public Offering in the Taiwan Stock Market
43. Study on the Relationship Between Dividend, Business Cycle, Institutional Investor and Stock Risk
44. From traditional innovation to green innovation: How an occurrence of natural disasters influences sustainable development?
45. Understanding the behavior of ESG in both OPEC and non‐OPEC countries? The implications for sustainable development reaching
46. Toward sustainable development: Does the rising oil price stimulate innovation in climate change mitigation technologies?
47. Does climate vulnerability promote green investment under energy supply restriction?
48. Impact of digital transformation on performance of environment, social, and governance: Empirical evidence from China
49. Identifying the nexus among environmental performance, digital finance, and green innovation: New evidence from prefecture-level cities in China
50. Black-Litterman Model and Momentum Strategy: Evidence of Taiwan Top 50 ETF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.